Brain metastases and immunotherapy in lung cancer — does it reach the brain?

For most people, not first. Brain deposits usually need local treatment before or alongside anything systemic. Immunotherapy is considered only when there is no targetable driver mutation, the brain lesions are small or already controlled, symptoms are settled, and steroid doses are low. It is a later step in a sequence, not the opening move.

Brain metastases are common in lung cancer. Published series report them in a substantial minority of people with non-small cell lung cancer at some point during the illness, and lung cancer is the single largest source of secondary brain tumours in India. That combination is exactly why this page begins with what immunotherapy cannot do quickly, rather than with what it can do eventually.

There are five common reasons a checkpoint inhibitor is not where treatment starts. The lesion is causing headache, weakness, seizures or vision change, and needs relief in days, not months. The lesion is large or pressing on surrounding brain, so local control is the only reliable answer. The biopsy shows a sensitising EGFR mutation or an ALK rearrangement, and a targeted oral drug designed to cross into the nervous system is the better systemic choice. Higher-dose steroids are running to control swelling, and those steroids work against the very immune activation a checkpoint inhibitor depends on. Or the spread is leptomeningeal — across the linings of the brain and cord — where evidence for checkpoint blockade is genuinely thin.

The evidence base here is also younger than most people assume. Registration trials for checkpoint inhibitors in lung cancer largely excluded patients with active, untreated brain metastases, so much of what is known comes from small dedicated studies and from patients whose brain disease was already treated and stable. NCCN and ESMO guidance reflects that caution. Anyone quoting you a confident number for brain disease is going beyond what the published data supports.

None of this means the answer is no. It means the order matters more here than almost anywhere else in lung cancer care. At CION, driver-mutation and PD-L1 testing is coordinated through accredited partner pathology laboratories, brain MRI and response imaging are coordinated at partner imaging centres, and the plan is set by a tumour board rather than by one doctor alone.

What has been published is modest and comes from small studies. In dedicated series of highly selected patients — untreated, small, symptom-free brain metastases, PD-L1 positive non-small cell lung cancer, no driver mutation, low or no steroids — intracranial objective responses were reported in roughly 20 to 30 percent. That is measurable shrinkage of the brain lesions on imaging, in a group, indicative as of August 2026 and consistent with NCCN and ESMO guidance. It is not a survival figure, and it says nothing about what will happen in one individual.

Brain and body can also respond differently in the same patient. A chest scan improving does not mean the brain lesions are improving, which is why brain imaging is repeated on its own schedule rather than assumed from the body scan.

Simplified for patient education and consistent with NCCN, ESMO and ASCO guidance, indicative as of August 2026. Your radiotherapy itself is delivered at an NABH-accredited partner centre; CION Cancer Clinics coordinates your treatment plan, your oncology team and your care throughout. Only your treating team, reading your own MRI and biopsy, can say which row applies to you.

1. 1

   Brain MRI with contrast — not a PET-CT

   MRI with contrast is the test that shows how many lesions there are, how big, and where. PET-CT cannot reliably see them. MRI and response-assessment imaging are coordinated at partner imaging centres.

2. 2

   Settle symptoms and pressure

   Swelling around a lesion is controlled with a steroid at the lowest dose that works, and anti-seizure medicine is added if there has been a fit. This is done for safety, not for the cancer, and it happens before any treatment decision.

3. 3

   Driver-mutation testing, then PD-L1

   EGFR, ALK, ROS1 and other targetable alterations are looked for first. A positive result usually points to a nervous-system-penetrant oral drug instead. PD-L1 scoring follows, and it matters only once the driver question is settled.

4. 4

   Decide local control with the radiation oncologist

   Stereotactic radiosurgery, neurosurgery for a single large lesion, or whole-brain radiation where deposits are numerous. Radiotherapy is delivered at an NABH-accredited partner centre, with CION coordinating the plan and the team.

5. 5

   Bring the steroid down before the first infusion

   Higher-dose steroids running when a checkpoint inhibitor starts are associated with reduced benefit. Once local treatment has settled the swelling, the dose is usually reduced. Your team decides that timing. Never adjust a steroid yourself.

6. 6

   Start systemic therapy — or decide not to

   If a checkpoint inhibitor is chosen, it is given as day care at CION with blood tests before each cycle. A tumour board weighs it against targeted therapy, chemotherapy, radiation alone and supportive care. Choosing not to give systemic therapy is a legitimate outcome.

7. 7

   Re-scan the brain on its own schedule

   Brain MRI is repeated at intervals your oncologist sets, independently of body imaging, because the two can diverge. Repeat MRI is a running cost across the treatment and any estimate you are given is indicative, as of August 2026.

• Steroids become the central problem — they relieve swelling and they suppress the immune response the treatment depends on. The plan works around that tension rather than ignoring it.
• Growth on a brain scan is not watched — elsewhere, early enlargement can be immune cells arriving. Inside the skull there is no spare room, so it is investigated promptly.
• Radiation necrosis mimics recurrence — months after radiosurgery, treatment damage can look like a returning tumour on a standard MRI. Perfusion MRI or specialist review separates them.
• Timing of radiation and infusions is a real decision — giving radiosurgery and a checkpoint inhibitor close together is done at some centres and separated at others. Ask what your team is doing and why.
• Driving and being alone need discussing — if there has been a seizure or weakness, driving stops until your doctor says otherwise, and someone should know where you are.
• Caregivers become the early-warning system — confusion, personality change and word-finding trouble are usually noticed by family first, not by the patient.
• Neurological red flags are emergencies — a sudden severe headache, repeated vomiting, a seizure, new one-sided weakness, sudden vision loss or new confusion means going to the nearest emergency room now. If you cannot reach your treating doctor, call 1800 202 8726. Do not manage these at home and do not wait for the next appointment.
• Cost runs across cycles and scans — infusions, repeat brain MRI and radiation each carry their own bill. Cover under Aarogyasri, Ayushman Bharat, CGHS, ECHS or private insurance is checked before you start, and any estimate is indicative, as of August 2026.

Consultations at CION run 45 minutes, and the option of not starting systemic treatment is discussed as seriously as starting it. Decisions for healing, not billing.

• Adjuvant Immunotherapy After Lung Cancer Surgery — the earlier-stage conversation, where the aim is to lower the chance of spread before the brain is ever involved.
• Adjuvant Immunotherapy After Melanoma Surgery — how benefit and risk are weighed after surgery in the cancer type where brain spread is best documented.
• Acral and Mucosal Melanoma in India: Does Immunotherapy Work? — the same principle in another form: the subtype on your report, not the treatment name, decides what is likely to help.
• Immunotherapy at CION Cancer Clinics — how the whole pathway runs, from biomarker testing to day care infusions and follow-up.

This page is general patient education about immunotherapy where lung cancer has spread to the brain. It does not interpret any individual scan or report, and it does not recommend a specific medicine. Biomarker testing and imaging are coordinated at accredited partner laboratories and imaging centres, and radiotherapy is delivered at an NABH-accredited partner centre. Evidence in brain metastases remains limited because most registration trials excluded active brain disease. Guideline positions and cost figures are indicative, as of August 2026, and change over time. Bring your reports to a consultation for an assessment of your own situation.

Families hear “it has spread to the brain” every week

The words land hard, and the internet answers badly. Our team takes 45 minutes to explain what your own scan and biopsy actually mean, and what can be done in what order.